David Scheinberg

Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon on December 1, 1986 and is headquartered in New York, NY.

Global Positioning System (GPS) is a government-operated satellite-based navigation system that provides location and time information. The private company is based in Woburn, MA. The GPS modernization program has added new civil signals to the system, including the L2C and L5 signals. The ground control and space segments of the GPS are also described on the gps.gov website. The website provides information about GPS accuracy and potential interference from other communication networks. Additionally, the website offers public information in Arabic and Mandarin Chinese about the GPS. The National Aeronautics and Space Administration (NASA) also holds meetings of the National Space-Based Positioning, Navigation and Timing (PNT) Advisory Board to discuss GPS-related topics.

Memorial Sloan-Kettering Cancer Center operates as a private cancer center. It offers cancer care services to adult; and child and teen patients. Its services include risk assessment and screening; diagnosis and treatment; clinical trials; patient and caregiver education; and pediatric clinical trials. The company was founded by John J. Astor and Charlotte Astor in 1884 and is headquartered in New York, NY.

Part of Memorial Sloan Kettering Cancer Center, Tri-Institutional Therapeutics Discovery Institute, Inc. is an American New York-based company that encourages the Tri-Institutional community to advance their biological discoveries to preclinical studies. The company provides technical support for academic projects and offers a menu of services to translate research discoveries from bench to bedside. Tri-Institutional Therapeutics Discovery Institute achieves its mission by leveraging the infrastructure, staff, and intellectual capital of its academic and industry partners, as well as the generous support of philanthropists. The company was founded by David A. Scheinberg.

Sapience Therapeutics, Inc. focuses on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Its drug development program involves translating science into novel therapies, and initial goal is to develop a first-in-class treatment for glioblastoma multiforme, which is the most severe and deadly form of brain cancer. The company was founded by Barry Kappel and Isaac Blech in 2015 and is headquartered in Scarsdale, NY.

SELLAS Life Sciences Group, Inc. /Old/ is based in New York, NY. SELLAS Life Sciences Group, Inc. is a clinical-stage biopharmaceutical company.